stoxline Quote Chart Rank Option Currency Glossary
Exact Sciences Corporation (EXAS)
67.28  2.31 (3.56%)    11-29 10:48
Open: 66.02
High: 67.98
Volume: 341,574
Pre. Close: 64.97
Low: 66.02
Market Cap: 12,168(M)
Technical analysis
2023-11-29 10:16:32 AM
Short term     
Mid term     
Targets 6-month :  80.89 1-year :  94.48
Resists First :  69.26 Second :  80.89
Pivot price 63.85
Supports First :  62.56 Second :  58.43
MAs MA(5) :  65.96 MA(20) :  64.06
MA(100) :  75.77 MA(250) :  71.48
MACD MACD :  0.2 Signal :  -0.4
%K %D K(14,3) :  71.2 D(3) :  68.2
RSI RSI(14): 56.7
52-week High :  100.76 Low :  43.68
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ EXAS ] has closed below upper band by 14.9%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 65.52 - 65.96 65.96 - 66.32
Low: 62.73 - 63.16 63.16 - 63.51
Close: 64.34 - 65.04 65.04 - 65.62
Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Headline News

Tue, 28 Nov 2023
EXAS Quantitative Stock Analysis - Nasdaq

Tue, 28 Nov 2023
Top Research Reports for Microsoft, Broadcom & Wells Fargo - Nasdaq

Tue, 28 Nov 2023
Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain - Yahoo Finance

Tue, 21 Nov 2023
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech ... - Nasdaq

Mon, 20 Nov 2023
2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030 - The Motley Fool

Fri, 17 Nov 2023
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Diagnostics & Research
Shares Out 181 (M)
Shares Float 179 (M)
Held by Insiders 0.9 (%)
Held by Institutions 88.7 (%)
Shares Short 7,570 (K)
Shares Short P.Month 7,580 (K)
Stock Financials
EPS -1.59
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.26
Profit Margin -11.8 %
Operating Margin -10.4 %
Return on Assets (ttm) -3.5 %
Return on Equity (ttm) -9.1 %
Qtrly Rev. Growth 20.1 %
Gross Profit (p.s.) 8.34
Sales Per Share 13.32
EBITDA (p.s.) -0.8
Qtrly Earnings Growth 0 %
Operating Cash Flow 139 (M)
Levered Free Cash Flow 3 (M)
Stock Valuations
PE Ratio -42.83
PEG Ratio -0.5
Price to Book value 3.92
Price to Sales 5.07
Price to Cash Flow 88.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android